Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from fibrosis such as pulmonary fibrosis, hepatic fibrosis and renal fibrosis, the fibrosis of tissues may be inhibited. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of fibronectin, CTGF2, ?-SMA, collagen 1A and the like during treatment of TGF-?. Therefore, the pharmaceutical composition according to the present invention may be effectively used in the prevention or treatment of fibrosis.

Abstract: The present invention relates to a mitochondrion containing a compound having the anticancer efficacy and uses thereof. It was confirmed that the mitochondrion efficiently deliver the compound to the tumor, and the anticancer effect of the mitochondrion containing the compound was confirmed. In particular, when an antibody or a fragment thereof that specifically binds to a tumor is bound to the surface of mitochondrion, the compound may be delivered specifically to the tumor. Therefore, the mitochondrion containing the compound according to the present invention may be effectively used for the treatment of cancer because the side effects of the compound are few.

Abstract: Provided are a method for obtaining active mitochondria by freezing platelets and a use of isolated mitochondria, and more specifically, to a method for obtaining mitochondria by thawing platelets after freezing the same and a pharmaceutical composition containing the mitochondria obtained by the method as an active ingredient. The present disclosure, by providing a method for obtaining mitochondria by thawing platelets in a frozen state in a preservation solution, not only enables to obtain mitochondria in which the activity is stably maintained, but also enables to provide a commercial value for donor platelets that are discarded after refrigeration for a short period of time. Additionally, the pharmaceutical composition containing platelet-derived mitochondria obtained by the above method may be effectively used to treat various diseases caused by mitochondrial dysfunction.

Abstract: Provided is a composition for injection containing isolated mitochondria. More specifically, provided is a liquid composition for injection containing glycine, saccharide, buffer, and mitochondria, and a pharmaceutical composition comprising the liquid composition for injection as an active ingredient. The liquid composition for injection according to the present disclosure is capable of securing the safety of a mitochondrial therapeutic and maintaining the activity of mitochondria, by enhancing the stability of mitochondria for prevention or treatment of mitochondria-related diseases and preventing and inhibiting formation of blood clots in the blood of a subject who is administered with the same.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-? which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis.

Abstract: Disclosed herein are water-soluble microneedle spicules for scrubs and a non-aqueous cosmetic composition containing the same. More specifically, the present invention relates to water-soluble microneedle spicules for scrubs, which are in the shape of a triangular pyramid or sexangular pyramid and characterized in that at least any one among the interior angles of the pyramid base of the spicules for scrubs is 90 degrees or less; and a non-aqueous cosmetic composition containing the same.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1?, TNF-?, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.

Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.

Abstract: Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.

Abstract: A composition for controlling the shape of the micro-spicule particles, micro-spicule particles molded by water-soluble materials, and its method for producing the micro-spicule particles molding with water-soluble materials having a sharp pointed vertex without tip collapse by controlling the amount of the alkylated glycerin compound in the solution loaded onto the multiple pattern engraved mold. The shape of molded micro-spicules can be controlled by using alkylated glycerin and thus various types of water-soluble micro-spicule particles can be prepared when mixed with a non-aqueous formulation and applied to the skin, the water-soluble micro-spicule particles prepared by the present invention provide advantageous scrubbing effect.

Abstract: The present invention relates to a non-aqueous cosmetic composition comprising water-soluble scrub particles containing a polypeptide or a cell culture component. More specifically, the present invention relates to a non-aqueous cosmetic composition comprising 0.01 wt % to 15 wt % of hard and angulated water-soluble scrub particles containing cell culture components or various polypeptides including a peptide and an oligopeptide. Further, the cosmetic composition of the present invention provides a non-aqueous cosmetic composition which does not comprise active ingredients, but comprises water-soluble excipient scrub particles for maintaining or improving a scrubbing effect and adjusting viscosity or volume.

Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.

Abstract: Disclosed herein are water-soluble microneedle spicules for scrubs and a non-aqueous cosmetic composition containing the same. More specifically, the present invention relates to water-soluble microneedle spicules for scrubs, which are in the shape of a triangular pyramid or sexangular pyramid and characterized in that at least any one among the interior angles of the pyramid base of the spicules for scrubs is 90 degrees or less; and a non-aqueous cosmetic composition containing the same.

Abstract: The present invention relates to a non-aqueous cosmetic composition comprising water-soluble scrub particles containing a polypeptide or a cell culture component. More specifically, the present invention relates to a non-aqueous cosmetic composition comprising 0.01 wt % to 15 wt % of hard and angulated water-soluble scrub particles containing cell culture components or various polypeptides including a peptide and an oligopeptide. Further, the cosmetic composition of the present invention provides a non-aqueous cosmetic composition which does not comprise active ingredients, but comprises water-soluble excipient scrub particles for maintaining or improving a scrubbing effect and adjusting viscosity or volume.

Abstract: The present invention relates to a primer for detection of cytochrome P450 hydroxylase specific to polyene and a method for detecting a strain of bacteria which produces polyene, by using the primer. More particularly, the present invention is directed in a forward degenerate primer of following sequence (I) and a reverse degenerate primer of following sequence (II), which are complementary to conserved region which resides in the polyene-specific CYP (cytochrome P450 hydroxylose) encoding sequences: (I) 5?-TGGATCGGCGACGACCGSVYCGT-3? and (II) 5?-CCGWASAGSAYSCCGTCOTACTT-3?, wherein S indicated Guanine or Cytosine, V indicates Adrenine, Guanine or Cytosine, Y indicates Thymine or Cytosine and W indicates Thymine or Adenine.

Abstract: A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of: (a) contacting the inclusion bodies with an aqueous alcohol solution at an alkaline pH to solubilize said protein; and (b) bringing the solubilized protein into contact with a mild oxidizing agent to refold and form intramolecular disulfide bonds between cysteine residues of said protein.

Abstract: The present invention relates to water-insoluble, crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof, where the amide derivatives of hyaluronic acid are characterized by crosslinking, of polymer or oligomer having two or more amine groups, with hyaluronic acid or its hyaluronate salts through amidation reaction. The water-insoluble, crosslinked amide derivatives of hyaluronic acid according to the present invention may be diversely used for prevention of adhesion after surgical operation, correction of facial wrinkles, dermal augmentation, tissue engineering, osteoarthritic viscosupplement etc.